# Schedules of Controlled Substances: Placement of 3-Methoxyphencyclidine in Schedule I > **Author:** Benjamin Caplan, MD (ABFM Board Certified, MA Lic. #240562, NPI: 1962722637) > **Publisher:** CED Clinic (https://cedclinic.com) > **Canonical URL:** https://cedclinic.com/dea-drug-scheduling-updates-3-methoxyphencyclidine-schedule-i/ > **Published:** 2026-04-11T18:54:02-04:00 | **Last Modified / Clinically Audited:** 2026-09-28T10:24:52-04:00 > **Clinical Summary:** Explore DEA drug scheduling updates on 3-methoxyphencyclidine's placement in Schedule I and its regulatory impact. --- ✦ New CED Clinical Relevance #70 Notable Clinical Interest Emerging findings or policy developments worth monitoring closely. ⚒ Policy Watch  |  Federal Register PolicySafetyResearch Clinical Summary The U.S. Drug Enforcement Administration has placed 3-methoxyphencyclidine (3-MeO-PCP), a synthetic phencyclidine analog, into Schedule I of the [Controlled Substances](https://cedclinic.com/dea-scheduling-cannabis-policy-march-15-2026/) Act due to its high abuse potential and lack of accepted medical use. This regulatory action reflects the ongoing challenge of novel psychoactive substances that emerge in illicit drug markets and circumvent existing [drug scheduling](https://cedclinic.com/controlled-substances-rescheduling-2026/). While not directly related to cannabis, this scheduling demonstrates the regulatory framework and enforcement mechanisms that also apply to cannabinoid derivatives and synthetic cannabis analogs, which have similarly prompted scheduling actions to prevent [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) harms. Clinicians should be aware that novel cannabinoid products and other emerging synthetic drugs may not yet be formally scheduled, creating gaps in regulation and safety oversight that can affect patient exposure and poisoning risk. Understanding the DEA’s scheduling rationale for designer drugs informs how clinicians might anticipate future regulatory actions on unregulated or semi-regulated cannabis products claiming [therapeutic benefits](https://cedclinic.com/therapeutic-benefits-of-thc/). Clinicians caring for patients with substance use concerns should recognize that these designer substances continue to present detection and treatment challenges in [clinical practice](https://cedclinic.com/cannabis-reproductive-health-women-clinical-evidence/). Clinical Perspective The DEA’s placement of 3-methoxyphencyclidine (3-MeO-PCP), a novel synthetic cathinone analog, into Schedule I reflects ongoing regulatory responses to emerging designer drugs that evade existing controls through minor structural modifications. While this scheduling action addresses a specific compound, it underscores the broader challenge that clandestine chemists continuously synthesize novel psychoactive substances faster than regulatory frameworks can classify them, complicating [public health](https://cedclinic.com/cannabis-mold-contamination-risks-recall-safety/) surveillance and clinical response. Healthcare providers should be aware that patients presenting with acute neuropsychiatric symptoms, severe agitation, or dissociative episodes may have used novel PCP analogs that are not captured by standard urine drug screens, potentially delaying accurate diagnosis and appropriate management. The variability in potency, purity, and composition of street samples of these compounds, combined with limited pharmacological and toxicological data, means clinical assessment must rely on careful 💬 Join the Conversation Have a question about how this applies to your situation? [Ask Dr. Caplan →](https://benjamincaplan.com/ask-dr-caplan) Want to discuss this topic with other patients and caregivers? [Join the forum discussion →](https://cedclinic.com/interact/discussion-forums/) Have thoughts on this? Share it: [𝕏 Share on X](https://twitter.com/intent/tweet?text=Just+read+this+on+CEDclinic.com%3A+Schedules+of+Controlled+Substances%3A+Placement+of+3-Methoxyphencyclidine+%281-%281-%283-Methoxyphenyl%29cyclo...+%40drcaplan&url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F03%2F23%2F2026-05618%2Fschedules-of-controlled-substances-placement-of-3-methoxyphencyclidine)[in Share on LinkedIn](https://www.linkedin.com/sharing/share-offsite/?url=https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F03%2F23%2F2026-05618%2Fschedules-of-controlled-substances-placement-of-3-methoxyphencyclidine)[🦅 Share on BlueSky](https://bsky.app/intent/compose?text=Just+read+this%3A+Schedules+of+Controlled+Substances%3A+Placement+of+3-Methoxyphencyclidine+%281-%281-%283-Methoxyphenyl%29cyclo...+--+via+%40drcaplan.bsky.social+https%3A%2F%2Fwww.federalregister.gov%2Fdocuments%2F2026%2F03%2F23%2F2026-05618%2Fschedules-of-controlled-substances-placement-of-3-methoxyphencyclidine)[📷 Follow on Instagram](https://www.instagram.com/drbenjamincaplan/)[📝 Read more on Substack](https://substack.com/@doctorapproved)[🔔 Subscribe via RSS](https://cedclinic.com/category/cannabis-news/feed/) Further Reading Research Digest[Research Digest: 4 Recent Studies – April 09, 2026](https://cedclinic.com/4-recent-cannabis-research-studies-april-2026/) CED Clinic BlogWant to help garden birds? Don’t feed them in warmer months, says RSPB Evidence Watch[Astrocytic GPR55 receptors promote glycolysis.](https://cedclinic.com/astrocytic-gpr55-receptors-glycolysis-brain-metabolism/) Related Articles - [High Marijuana Taxes Don’t Effectively Deter Use, Study Shows, Contrary To NYT Editorial …](https://cedclinic.com/cannabis-tax-increases-patient-use-study-insights/) - [DEA admits legal cannabis isn’t increasing youth use (Newsletter: March 19, 2026)](https://cedclinic.com/legal-cannabis-youth-use-data-no-increase/) - [Drug legalization: Basel-Stadt takes positive stock after three years of cannabis dispensing](https://cedclinic.com/basel-stadt-cannabis-dispensing-program/) 📰 Source: [https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine](https://www.federalregister.gov/documents/2026/03/23/2026-05618/schedules-of-controlled-substances-placement-of-3-methoxyphencyclidine) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) Physician-Led, Whole-Person Care A doctor who takes the time to truly understand you. Personal care that starts with listening and is guided by experience and ingenuity. Health, Longevity, Wellness One-on-One Cannabis Guidance Metabolic Balance [Leave a Message](https://cedclinic.com/contact/) [Metabolic Care](https://cedclinic.com/metabolic/metabolic-how-it-works/) [Medical Consulting](https://cedclinic.com/book/) [Cannabis Care](https://cedclinic.com/book/) [https://cedclinic.com/contact/](https://cedclinic.com/contact/) RELATED READING AT CED CLINIC Continue exploring the evidence [Schedules of Controlled Substances: Placement of CUMYL-PEGACLONE in Schedule I](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) Review the DEA's scheduling of CUMYL-PEGACLONE, another synthetic cannabinoid placed in Schedule I. [Learn More](https://cedclinic.com/synthetic-cannabinoids-schedule-i-designation/) [Schedules of Controlled Substances: Placement of MDMB-4en-PINACA in Schedule I](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) Explore the regulatory action placing MDMB-4en-PINACA in Schedule I and its implications. [Read Details](https://cedclinic.com/mdmb-4en-pinaca-schedule-i-placement/) [Schedules of Controlled Substances: Placement of Diphenidine in Schedule I](https://cedclinic.com/diphenidine-regulatory-scheduling-update-schedule-i/) Understand the DEA's scheduling of Diphenidine as a Schedule I controlled substance. [Discover More](https://cedclinic.com/diphenidine-regulatory-scheduling-update-schedule-i/) ### Related --- ### Verification & Medical Governance - **Lead Clinical Author:** Benjamin Caplan, MD - **Credentials:** Board Certified in Family Medicine (ABFM), Founder & CMO CED Clinic & CED Foundation, Author of *The Doctor-Approved Cannabis Handbook* (Penguin Random House). - **Clinical Scale:** 350,000+ lifetime evaluations overseen; 81,008-patient Real-World Evidence Registry (`~/.ced_rwe_vault.db`); 125,000+ peer-reviewed study literature observatory (`http://localhost:8768/api/explorer/terminal`). - **License Verification:** Commonwealth of Massachusetts License #240562 (https://checkahealthlicense.mass.gov/). - **NPI Registry:** 1962722637 (https://npiregistry.cms.hhs.gov/provider-view/1962722637). - **Ethics & Data Privacy:** Clinical registry observations adhere strictly to HIPAA Safe Harbor de-identification (45 CFR § 164.514(b)) and criteria for secondary research exemption under 45 CFR § 46.104(d)(4).